Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.19−0.04 (-15.51%)
Close on Nov 18, 2026Market cap $14.06MP/E –Yield –
Acumen Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Acumen Pharmaceuticals's total assets was $85.57M at Sep 30, 2026. For fiscal 2025 it was $122.83M, down 48.6% from the year before. The highest annual figure on record is $310.13M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.83M | -48.6% |
| FY2024 | Dec 31, 2024 | $238.99M | -22.9% |
| FY2023 | Dec 31, 2023 | $310.13M | +57.8% |
| FY2022 | Dec 31, 2022 | $196.59M | -14.6% |
| FY2021 | Dec 31, 2021 | $230.33M | +418.4% |
| FY2020 | Dec 31, 2020 | $44.43M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $85.57M | -39.8% |
| Q2 FY2026 | Jun 30, 2026 | $116.01M | -32.5% |
| Q1 FY2026 | Mar 31, 2026 | $133.63M | -34.6% |
| Q4 FY2025 | Dec 31, 2025 | $122.83M | -48.6% |
| Q3 FY2025 | Sep 30, 2025 | $142.22M | -46.7% |
| Q2 FY2025 | Jun 30, 2025 | $171.90M | -40.5% |
| Q1 FY2025 | Mar 31, 2025 | $204.48M | -32.1% |
| Q4 FY2024 | Dec 31, 2024 | $238.99M | -22.9% |
| Q3 FY2024 | Sep 30, 2024 | $266.98M | -6.8% |
| Q2 FY2024 | Jun 30, 2024 | $288.91M | +62.9% |
| Q1 FY2024 | Mar 31, 2024 | $300.97M | +60.2% |
| Q4 FY2023 | Dec 31, 2023 | $310.13M | +57.8% |
| Q3 FY2023 | Sep 30, 2023 | $286.37M | +40.9% |
| Q2 FY2023 | Jun 30, 2023 | $177.41M | -16.2% |
| Q1 FY2023 | Mar 31, 2023 | $187.86M | -14.6% |
| Q4 FY2022 | Dec 31, 2022 | $196.59M | -14.6% |
| Q3 FY2022 | Sep 30, 2022 | $203.26M | -13.4% |
| Q2 FY2022 | Jun 30, 2022 | $211.68M | +190.2% |
| Q1 FY2022 | Mar 31, 2022 | $220.09M | +395.4% |
| Q4 FY2021 | Dec 31, 2021 | $230.33M | – |
| Q3 FY2021 | Sep 30, 2021 | $234.85M | – |
| Q2 FY2021 | Jun 30, 2021 | $72.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $44.43M | – |
See a number that looks wrong?